A61P 43 - Drugs for specific purposes, not provided for in groups

Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
10/2006
10/24/2006	CA2158400C Synthesis of 3-[4-(2-aminoethoxy)-benzoyl]-2-aryl-6-hydroxybenzo[b]thiophenes
10/19/2006	WO2006110406A2 Compositions comprising probiotic and sweetener components
10/19/2006	WO2006110393A1 Inorganic materials for hemostatic modulation and therapeutic wound healing
10/19/2006	WO2006110118A1 Cytoprotection preparation
10/19/2006	WO2006109867A1 PYRAZOLO[1,5-a]PYRIDINE DERIVATIVE OR MEDICALLY ACCEPTABLE SALT THEREOF
10/19/2006	WO2006109846A1 Triazole derivative and the use thereof
10/19/2006	WO2006109762A1 Novel process for producing ramosetron or its salt
10/19/2006	WO2006109737A1 Pranlukast hydrate-containing preparation having relieved bitterness
10/19/2006	WO2006109642A1 Pharmaceutical composition and method using antifungal agent in combination
10/19/2006	WO2006109633A1 Substituted indole compound
10/19/2006	WO2006108488A1 Tricyclic azole derivatives, their manufacture and use as pharmaceutical agents
10/19/2006	WO2006108354A1 1-(substituted phenyl)-5- methyl- 2 - (1h) pyridone in the manufacture of medicaments for treating fibrosis in organs or tissues
10/19/2006	WO2006108218A1 Use of neuropeptide y (npy) and agonists and antagonists thereof for tissue regeneration
10/19/2006	WO2003027637A3 Assessment of neurons in the arcuate nucleus to screen for agents that modify feeding behavior
10/19/2006	US20060235239 Tetrafluorobenzyl derivatives and pharmaceutical composition for preventing and treating acute and chronic neurodegenerative diseases in central nervous system containing the same
10/19/2006	US20060235072 Potassium channel opener
10/19/2006	US20060235055 Therapeutic agents useful for treating pain
10/19/2006	US20060235049 1-{3-[4-(1-Methyl-pyrrolidin-2-yl)-phenoxy]-propyl}-piperidine, and 1-Benzyl-4-[4-(3-piperidin-1-yl-propoxy)-phenyl]-piperidin-4-ol; histamin receptor antagonist; antidepressant; upper airway allergies, nasal congestion, allergic rhinitis, cognitive dysfunction, schizophrenia, manic disorders
10/19/2006	US20060235045 Therapeutic agent for chronic obstructive pulmonary disease and method for treatment for chronic obstructive pulmonary disease with the same
10/19/2006	US20060235033 Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of macrophage colony stimulating factor receptor
10/19/2006	US20060235027 Inhibitors of cdc25 phosphatases
10/19/2006	US20060235026 Quinoline-4-Carboxamide Derivatives as NK-3 and NK-2 Receptor Antagonists
10/19/2006	US20060235023 Inhibitors of macrophage migration inhibitory factor and methods for indentifying the same
10/19/2006	US20060235019 Substituted quinazolinone compounds
10/19/2006	US20060235002 Novel physiologically active substance
10/19/2006	US20060234991 Combinations for the treatment of immunoinflammatory disorders
10/19/2006	US20060234990 Compositions of boswellic acids derived from Boswellia serrata gum resin, for treating lymphoproliferative and autoimmune conditions
10/19/2006	US20060234980 Antiinflammatory agent, agent for preventing/ameliorating allergic diseases and functional food
10/19/2006	US20060234957 Adiponectin expression promoter
10/19/2006	US20060234955 Cardiac glycosides to treat cystic fibrosis and other il-8 dependent disorders
10/19/2006	US20060234945 Ophthalmic therapeutic composition
10/19/2006	US20060234942 Use of at least one $g(a)62 casein peptide with angiotensin i converting enzyme inhibiting activity for preparing medicines, food products and food complements
10/19/2006	US20060234932 Prolonged efficacy of islet neogenesis therapy methods with a gastrin/CCK receptor ligand and an EGF receptor ligand composition in subjects with preexisting diabetes
10/19/2006	US20060234922 Remedy for corneal failure
10/19/2006	US20060234913 Orally administering insulin and delivery agent 4-[(4-chloro, 2-hydroxybenzoyl)amino]butanoic acid that facilitates the absorption of insulin from the gastrointestinal tract; diabetes mellitus; bioavailability comparable to injection; treating diabetes without the drawbacks of systemic hyperglycemia
10/19/2006	US20060234344 Protein kinases
10/19/2006	US20060234343 deletion of residues in the CR2 domain of the EGFR ectodomain gives rise to a truncated ectodomain with enhanced affinity for epidermal growth factors such as (EGF) and/or transforming growth factor-I (TGF- alpha ); psoriasis and tumor states
10/19/2006	US20060234307 Fusion proteins of of Fc domains with Ang-2 binding peptides; increases biological half life; angiopoietin-2 (Ang-2)
10/19/2006	US20060234294 Functional domain and associated molecule of dock2 essentially required in lymphocyte migration
10/19/2006	US20060234271 Methods for the diagnosis and treatment of metastatic prostate tumors
10/19/2006	US20060234224 Method and nucleic acids for the analysis of colon cell proliferative disorders
10/19/2006	US20060233902 Compositions and foods for improving lipid metabolism
10/19/2006	US20060233899 Treatment of Human Multiple Myeloma by Curcumin
10/19/2006	US20060233818 Organic compounds
10/19/2006	US20060233815 Agents for protection from neointimal formation in grafts comprising an nfkappab decoy
10/19/2006	US20060233806 Removal promoters and inhibitor for apoptosis cells in vivo
10/19/2006	US20060233804 IGF antagonist peptides
10/19/2006	US20060233778 Stability for injection solutions
10/19/2006	US20060233742 cyclic peptides blocking of the Casein Kinase II (CKII) phosphorylation domain; HPV-16 cervical carcinoma cells; peptides increase the sensitivity of the cells to the cytostatic effect of IFN
10/19/2006	US20060233724 Medicinal composition for peridontal pocket administration containing bisphosphonic acid derivative or its salt as the active ingredient
10/19/2006	US20060233719 Delivery of antidepressants through an inhalation route
10/19/2006	US20060233707 Process for producing an injectable medicament preparation
10/19/2006	DE112004001502T5 Neurobeschützende und Anti-Proliferationsverbindungen Neurobeschützende and anti-proliferative compounds
10/19/2006	CA2604835A1 Compositions comprising probiotic and sweetener components
10/19/2006	CA2604822A1 Novel process for producing ramosetron or its salt
10/19/2006	CA2603763A1 5-methyl-1-(substituted phenyl)-2-(1h)-pyridone in the manufacture of medicaments for treating fibrosis in organ or tissues
10/19/2006	CA2603457A1 Pyrazolo[1,5-a]pyridine derivatives or pharmaceutically acceptable salts thereof
10/19/2006	CA2602613A1 Inorganic materials for hemostatic modulation and therapeutic wound healing
10/19/2006	CA2602303A1 Tricyclic azole derivatives, their manufacture and use as pharmaceutical agents
10/18/2006	EP1712619A1 Preventive/remedy for cancer
10/18/2006	EP1712547A1 Bicycloester derivative
10/18/2006	EP1712237A2 Erythropoietin solution preparation stabilized with leucine, glutamic acid or lysine
10/18/2006	EP1712236A2 Methods of treating acne
10/18/2006	EP1712230A1 Pharmaceutical composition for xerophthalmia and xerostomia treatment
10/18/2006	EP1712228A2 Hyaluronic acid derivatives for the prevention and treatment of cutaneous scars
10/18/2006	EP1711617A1 Method and compositions for identifying anti-hiv therapeutics compounds
10/18/2006	EP1437358B1 Novel glycolipid and remedial agent for autoimmune disease containing the same as active ingredient
10/18/2006	EP1423112B1 A combination of quetiapine and zolmitriptan
10/18/2006	EP1358332B1 A serpin in bifidobacteria
10/18/2006	EP1345932B1 Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use
10/18/2006	EP1339714B1 Novel sulfonamide-substituted pyrazolopyridine derivatives
10/18/2006	EP1332206B1 Recombinant alpha-l-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof
10/18/2006	EP1212070B1 Plant extract mixtures (cissus, vernonia, brillantaisia) and their uses
10/18/2006	EP1107957B1 Pyrimidine compounds
10/18/2006	EP1072266B8 Thienylazolylalcoxyethanamines, their preparation and their application as medicaments
10/18/2006	EP1019500B1 Ifn receptor 1 binding proteins, dna encoding them, and methods of modulating cellular response to interferons
10/18/2006	EP0969862B1 Synthetic hiv gag genes
10/18/2006	EP0931063B1 N-substituted indol-3-glyoxylamid with antiasthmatic, antiallergic and immunosuppressive/immunomodulating effect
10/18/2006	EP0927252B1 Antibodies against interferon alpha/beta receptor
10/18/2006	EP0797664B1 Use of a human interleukin-11 receptor
10/18/2006	CN1849303A Novel heteroaryl derivative
10/18/2006	CN1849122A Method of treating cancer using fpt inhibitors and at least two antineoplastic agents
10/18/2006	CN1847261A Cyclic peptides as g-protein-coupled receptor antagonists
10/18/2006	CN1847229A Novel compounds
10/18/2006	CN1846718A Methods for the production of purified recombinant human uteroglobin for the treatment of inflammatory and fibrotic conditions
10/18/2006	CN1846699A Application of 1-(substituted phenyl)-5-methyl-2-(1H)-pyridone compound in preparing medicine for anti-other organifibrosis and tissue fibrosis except renal interstitial fibrosis
10/18/2006	CN1846697A New use of angiotensin ii antagonists
10/18/2006	CN1846517A Glossy ganoderma-three flower tea and its prepn process
10/18/2006	CN1280309C Erythropoietin with high specific activity
10/18/2006	CN1280291C Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors
10/18/2006	CN1280289C Alkoxy carbonylamino heteroaryl carboxylic acid derivatives as IP antagonists
10/18/2006	CN1280288C Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1)
10/18/2006	CN1280269C Aliphatic nitrogenous five-membered ring compounds
10/18/2006	CN1280267C Sulfonylaminocarboxylic acids
10/18/2006	CN1280259C Aryl aniline beta-2 adrenergic receptor agonists
10/18/2006	CN1279949C Chinese medicine for fat reducing and long life
10/18/2006	CN1279936C Medicine for treating coronary heart disease and angina pectoris and restenosis after intervention operation
10/18/2006	CN1279906C Use of thiolutin dioxide and its derivatives in the manufacture of a medicament for the treatment of cns disorders and a process for the preparation thereof
10/18/2006	CN1279898C Application of glycine in preparing medicine
10/17/2006	US7122687 Sodium salt formation of Mycophenolic acid

1 ... 382 383 384 385 386 387 388 389 390 391 392 393 394 395 396 397 398 399 400 401 402 ... 1564